The 10th EDCTP Forum will be held as a virtual meeting hosted from the Joaquim Chissano International Conference Centre in Maputo from 17 – 21 October 2021 on the theme of 'Equity in research for health.'
Pyramax sponsored symposium: Symposium at 10th EDCTP Forum: Main post-approval and real-life studies conducted and ongoing in parallel with the launch and scale-up of pyronaridine-artesunate (Pyramax®) in Africa
19th October, 13:00-14:00 (Mozambique local time)
Pyronaridine-artesunate is the latest ACT to be recommended by the WHO. Since its initial positive opinion through article 58 by the Europeans Medicine Agency and the start of registration worldwide in malaria-endemic countries, several post-approval/real-life studies have been carried out to support the local registrations as well as its deployment in African malaria-endemic countries.
- Efficacy and safety results from the post-registration WANECAM 1 and CANTAM studies Stephan Duparc, Chief Medical Officer, Medicines for Malaria Venture, Switzerland
- Efficacy and safety of 4 ACTs (pyronaridine-artesunate, artemether-lumefantrine, artesunate-amodiaquine and dihydroartemisinin-piperaquine) for the treatment of P. falciparum malaria in African pregnant women
Kassoum Kayentao, PYRAPREG-EDCTP Project Coordinator Malaria Research and Training Center, Department of Epidemiology of Parasitic Diseases, Faculty of Pharmacy, University of Sciences Techniques & Technology Bamako Mali
- Comparative efficacy and safety of pyronaridine-artesunate versus artemether-lumefantrine in the treatment of acute uncomplicated malaria among children in south-west Nigeria
Catherine Falade, Department of Pharmacology & Therapeutics, College of Medicine, University of Ibadan, Nigeria